Male breast cancer: A gender issue

Nature Clinical Practice Oncology

Volumn 3, Issue 8, 2006, Pages 428-437

  Nahleh, Zeina ^a   Girnius, Saulius ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; ANDROGEN RECEPTOR; ANTHRACYCLINE; ANTIANDROGEN; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; CYCLOPHOSPHAMIDE; CYPROTERONE ACETATE; CYTOCHROME P450 17; DIETHYLSTILBESTROL; DOXORUBICIN; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GONADORELIN AGONIST; GOSERELIN; LETROZOLE; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; TAMOXIFEN;

AGE DISTRIBUTION; ANTINEOPLASTIC ACTIVITY; AXILLARY LYMPH NODE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC RISK; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MALE; MALE BREAST; MASTECTOMY; MULTIMODALITY CANCER THERAPY; PARTIAL MASTECTOMY; PENETRANCE; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS, MALE; FEMALE; HUMANS; INCIDENCE; MALE; MASTECTOMY, MODIFIED RADICAL; PROGNOSIS; RISK FACTORS; UNITED STATES;

EID: 33747029983     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0564     Document Type: Review

References (113)

1. American Cancer Society (2005) Cancer Facts and Figures 2005. Atlanta: American Cancer Society
2. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER Stat Database: Incidence-SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002), National Cancer Institute, DCPPS, Surveillance Research Program, Cancer Statistics Branch
3. Sasco AJ et al. (1993) Review article: Epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 53: 538-549
4. Carlsson G et al. (1981) Male breast cancer. Clin Oncol 7: 149-155
5. Andersen JA and Gram JB (1982) Male breast at autopsy. Acta Pathol Microbiol Immunol Scand 90: 191-197
6. Giordano S et al. (2004) Breast carcinoma in men: A population-based study. Cancer 101: 51-57
7. Anderson WF et al. (2004) Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 83: 77-86
8. Pike MC et al. (1983) 'Hormonal' risk factors, 'breast tissue age'and the age-incidence of breast cancer. Nature 303: 767-770
9. Tischkowitz MD et al. (2002) Male breast cancer: Aetiology, genetics, and clinical management. Int J Clin Pract 56: 750-754
10. Weiss JR et al. (2005) Epidemiology of male breast cancer. Cancer Epidemol Biomarkers Prev 14: 20-26
11. Hultborn R et al. (1997) Prevalence of Klinefelter's syndrome in male breast cancer patients. Anticancer Res 14: 4293-4297
12. Ewertz M et al. (2001) Risk factors for male breast cancer - a case-control study from Scandinavia. Acta Oncol 40: 467-471
13. Hsing AW et al. (1998) Risk factors for male breast cancer (United States). Cancer Causes Control 9: 269-275
14. Jardines L et al. (2003) Breast cancer overview: Risk factors, screening, genetic testing, and prevention. In Cancer Management: A Multidisciplinary Approach, edn 7,163-187 (Eds Pazdur R et al.) New York: The Oncology Group
15. Brinton L et al. (2002) Epidemiology of Breast Cancer. In Cancer of the Breast, edn 5, 111-132. (Eds Donegan WL and Spratt JS) New York: Elsevier Science
16. Casagrande JT et al. (1988) A case control study of male breast cancer. Cancer Res 48: 1326-1330
17. Ford D et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676-689
18. Greene M (1997) Genetics of breast cancer. Mayo Clin Proc 72: 54-65
19. Friedman LS et al. (1997) Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 60: 313-319
20. Thorlacius S et al. (1997) Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 60: 1079-1084
21. Couch FJ et al. (1996) BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13: 123-125
22. Haraldsson K et al. (1998) BRCA2 germline mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 58: 1367-1371
23. Struewing JP et al. (1995) Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 57: 1-7
24. Giordano SH et al. (2002) Breast Cancer in men. Ann Intern Med 137: 678-687
25. Thorlacius S et al. (1997) A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 13: 117-119
26. Frank TS et al. (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 100,000 individuals. J Clin Oncol 20: 1480-1490
27. De Jong MM et al. (2002) Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet 39: 225-242
28. Fackenthal JD et al. (2002) Male breast cancer in Cowden syndrome patients with PTEN germline mutations. J Med Genet 39: 225-242
29. Wooster R et al. (1992) A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet 2: 132-134
30. Young IE et al. (2000) The CAG repeat within the androgen receptor gene in male breast cancer patients. J Med Genet 37: 139-140
31. Menin C et al. (2001) Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer. Cancer Lett 168: 31-36
32. Syrjakoski K et al. (2003) Androgen receptor gene alterations in Finnish male breast cancer. Breast Cancer Res Treat 77: 167-170
33. Lobaccaro JM et al. (1993) Androgen receptor gene mutation in male breast cancer. Hum Mol Genet 2: 1799-1802
34. Young IE et al. (2000) The CAG repeat within the androgen receptor gene in male breast cancer patients. J Med Genet 37: 139-140
35. Young IE et al. (1999) A polymorphism in the CYP17 gene is associated with male breast cancer. Br J Cancer 81: 141-143
36. Feigelson HS et al. (1998) Cytochrome p450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 58: 585-587
37. Dunning AM et al. (1998) No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer 77: 2045-2047
38. The CHEK2-Breast Cancer Consortium. (2002) Low penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31: 55-59
39. Ohayon T et al. (2004) CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer 108: 479-480
40. Syrjakoski K et al. (2004) CHEK2 1100delC is not a risk factor for male breast cancer population. Int J Cancer 108: 475-476
41. Neuhausen S et al. (2004) Role of CHEK2*1100del C in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer 108: 477-478
42. Cutuli B et al. (1995) Male breast cancer: Results of the treatment and prognostic factors in 397 cases. Eur J Cancer 3lA: 1960-1964
43. Goss PE et al. (1999) Male breast carcinoma: A review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer 85: 629-639
44. Gough DB et al. (1993) A 50-year experience of male breast cancer: Is outcome changing? Surg Oncol 2: 325-333
45. Heller KS et al. (1978) Male breast cancer: A clinicopathologic study of 97 cases. Ann Surg 188: 117-120
46. Ramantanis G et al. (1980) Breast cancer in the male: A report of 138 cases. World J Surg 4: 621-623
47. Ribeiro G et al. (1996) A review of the management of the male breast carcinoma based on an analysis of 420 treated cases. Breast 5: 141-146
48. Hittmair AP et al. (1998) Ductal carcinoma in situ in the male breast: A morphologic study of 84 cases of pure DCIS and 30 cases of DCIS associated with invasive carcinoma - a preliminary report. Cancer 83: 2139-2149
49. Kidwai N et al. (2004) Expression of androgen receptor and prostate-specific antigen in male breast carcinoma. Breast Cancer Res 6: R18-R23
50. Green LK and Kima M (1991) The use of immunohistochemistry in metastatic prostatic adenocarcinoma to the breast. Hum Pathol 22: 242-246
51. Stierer M et al. (1995) Male breast cancer: Austrian experience. World J Surg 19: 687-692
52. Salvadori B et al. (1994) Prognosis of breast cancer in males: An analysis of 170 cases. Eur J Cancer 30A: 930-935
53. Bruce DM et al. (1996) Male breast cancer: Clinico-pathologic features, immunocytochemical characteristics and prognosis. Eur J Surg Oncol 22: 42-46
54. Joshi MG et al. (1996) Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome. Cancer 77: 490-498
55. Guinee VF et al. (1993) The prognosis of breast cancer in males: A report of 335 cases. Cancer 71: 155-161
56. Scott-Conner CE et al. (1999) An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery 126: 775-780
57. Wagner JL et al. (1995) Carcinoma of the male breast: Update 1994. Med Pediat Oncol 24: 123-132
58. Winchester DJ (1996) Male breast cancer. Semin Surg Oncol 12: 364-369
59. Muir D et al. (2003) Male versus female breast cancers. A population-based comparative immuno-histochemical analysis. Arch Pathol Lab Med 127: 36-41
60. Wang-Rodriguez J et al. (2002) Male breast carcinoma: Correlation of ER, PR, Ki-67, HER2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol 15: 853-861
61. Donegan WL and Redlich PN (1996) Breast cancer in men. Surg Clin North Am 76: 343-363
62. Donegan WL et al. (1998) Carcinoma of the breast in males: A multiinstitutional survey. Cancer83: 498-509
63. Munoz cle Toro M et al. (1998) Proliferative activity and steroid hormone receptor status in male breast carcinoma. J Steroid Biochem Mol Biol 67: 333-339
64. Weber-Chappuis K et al. (1996) Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas. Eur J Cancer 32: 1686-1692
65. Rayson D et al. (1998) Molecular markers in male breast carcinoma. Cancer 83: 1947-1955
66. Ravandi-Kashani F and Hayes TG (1998) Male breast cancer: A review of the literature. Eur J Cancer 34: 1341-1347
67. Clark JL et al. (2000) Prognostic variables in male breast cancer. Am Surg 66: 502-511
68. Willsher PC et al. (1997) A comparison outcome of male breast cancer with female breast cancer. Am J Surg 173: 185-188
69. Shpitz B et al. (2000) Angiogenesis, p53, and c-erbB2 immunoreactivity and clinicopathological features in male breast cancer. J Surg Oncol 75: 252-257
70. Anelli A et al. (1995) Mutations of the p53 gene in male breast cancer. Cancer 75: 2233-2238
71. Pich A et al. (1996) DNA ploidy and p53 expression correlate with survival and cell proliferative activity in male breast carcinoma. Hum Pathol 27: 676-682
72. Joshi MG et al. (1996) Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome. Cancer 77: 490-498
73. Clark G (2000) Prognostic and predictive factors. In Diseases ofthe breast, edn 2, 489-514 (Ed. Harris JR) Philadelphia: Lippincott Williams & Wilkins
74. Fox SB et al. (1992) Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. J Pathol 166: 13-18
75. Kuroi K and Toi M (2003) Male breast cancer. Gan To Kagaku Ryoho 30: 599-605
76. Frangou EF et al. (2005) Angiogenesis in male breast cancer. World J Surg Oncol 3: 16
77. Hecht JR and Winchester DJ (1994) Male Breast cancer. Am J Clin Pathol 102 (suppi 1): S25-S30
78. Volm MD (2003) Male breast cancer. Curr Treat Options Oncol 4: 159-164
79. Hill AD et al. (1999) Sentinel node biopsy in male breast cancer. Eur J Surg Oncol 25: 442-443
80. Albo D et al. (2003) Evaluation of lymph node status in male breast cancer patients: A role for sentinel lymph node biopsy. Breast Cancer Res Treat 77: 9-14
81. De Cicco C et al. (2004) Sentinel node biopsy in male breast cancer. Nucl Med Common 25: 139-143
82. Cimmino VM et al. (2004) Efficacy of sentinel lymph node biopsy in male breast cancer. J Surg Oncol 86: 74-77
83. Ragaz I et al. (1997) Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337: 956-962
84. Schuchardt U et al. (1996) Adjuvant radiotherapy for breast carcinoma in men: A 20 year clinical experience. Am J Clin Oncol 19: 330-336
85. Ribeiro GG et al. (1996) A review of management of the male breast carcinoma based on an analysis of 420 treated cases. Breast 5: 141-146
86. Treves N and Holleb AJ (1955) Cancer of the male breast: A report of 146 cases. Cancer 8: 1239-1250
87. Bagley CS et al. (1987) Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol 10: 55-60
88. Patel HZ et al. (1989) Role of adjuvant chemotherapy in male breast cancer. Cancer 64: 1583-1585
89. Giordano SH et al. (2005) Adjuvant systemic therapy for male breast carcinoma. Cancer 104: 2359-2364
90. Margaria E et al. (2000) Therapy and survival in male breast carcinoma: a retrospective analysis of 50 cases. Oncol Rep 7: 1035-1039
91. Farrell J and Adair F (1941) Effect of orchiectomy on skeletal metastases from cancer of the male breast. Science 95: 654-657
92. Jaiyesimi IA et al. (1992) Carcinoma of the male breast. Ann Intern Med 95: 654-657
93. Patel JK et al. (1984) Metastatic breast cancer in males: Assessment of endocrine therapy. Cancer 53: 1344-1346
94. Kantarjian H et al. (1983) Hormonal therapy for metastatic male breast cancer. Arch Intern Med 142: 237-240
95. Ribeiro GG (1976) The results of diethylstilbestrol therapy for recurrent and metastatic carcinoma of the male breast. Br J Cancer 33: 465-467
96. Lopez M et al. (1985) Hormonal treatment of disseminated male breast cancer. Oncology 42: 345-349
97. Lopez M and Barduagni A (1982) Cyproterone acetate in advanced male breast cancer. Cancer 49: 9-11
98. Pannuti F et al. (1982) High-dose medroxyprogesterone acetate in advanced male breast cancer. Cancer Treat Rep 66: 1763-1765
99. Doberauer C et al. (1998) Advanced male breast cancer treatment with the LHRH analogue buserelin alone or in combination with the anti-androgen flutamide. Cancer 62: 474-478
100. Vorobiof DA and Falkson G (1987) Nasally administered buserelin inducing complete remission of lung metastases in male breast cancer. Cancer 59: 688-689
101. Ribeiro G (1983) Tamoxifen in the treatment of male breast carcinoma. Clin Radiol 34: 625-628
102. Ribeiro G and Swindell R (1992) Adjuvant tamoxifen for male breast cancer. Br J Cancer 65: 252-254
103. Baum M et al. (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial. Lancet 359: 2131-2139
104. Bonneterre J et al. (2000) Anastrozole versus tamoxifen as first line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 18: 3748-3757
105. Nabholtz JM et al. (2000) Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. J Clin Oncol 18: 3758-3767
106. Mouridsen H et al. (2001) Superior efficacy of letrozole versus tamoxifen as first line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596-2606
107. Handesman D (2001) Androgen actions and pharmacologic uses. In Endocrinology, 2232-2242 (Ed. Detroit ιJ) Philadelphia: WB Saunders
108. Harris AL et al. (1986) Role of aminoglutethimide in male breast cancer. Br J Cancer 54: 657-660
109. Patterson JS et al. (1980) Use of tamoxifen in advanced male breast cancer. Cancer Treat Rep 64: 801-804
110. Giordano SH et al. (2002) Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 25: 235-237
111. Italiano A et al. (2004) Complete remission obtained with letrozole in a man treated with metastatic breast cancer [French]. Rev Med Interne 25: 323-324
112. Zabolotny BP et al. (2004) Successful use of letrozole in male breast cancer: A case report and review of hormonal therapy for male breast cancer. J Surg Oncol 90: 26-30
113. Howell A et al. (2002) Fulvestrant is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396-3403